Literature DB >> 27175272

STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.

A M Eiring1, I L Kraft1, B D Page2, T O'Hare1, P T Gunning2, M W Deininger1.   

Abstract

Entities:  

Keywords:  BCR-ABL1-dependent resistance; BCR-ABL1-independent resistance; BP-5-087; CML stem cell; STAT3; TKI resistance; pSTAT3Y705

Year:  2014        PMID： 27175272      PMCID： PMC4851281          DOI： 10.1038/leusup.2014.3

Source DB:  PubMed          Journal:  Leuk Suppl        ISSN： 2044-5210


× No keyword cloud information.
  8 in total

1.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

Authors:  Susan M Graham; Heather G Jørgensen; Elaine Allan; Charlie Pearson; Michael J Alcorn; Linda Richmond; Tessa L Holyoake
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

2.  Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.

Authors:  Bin Zhang; Min Li; Tinisha McDonald; Tessa L Holyoake; Randall T Moon; Dario Campana; Leonard Shultz; Ravi Bhatia
Journal:  Blood       Date:  2013-01-08       Impact factor: 22.113

3.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors:  M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

4.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Authors:  Amie S Corbin; Anupriya Agarwal; Marc Loriaux; Jorge Cortes; Michael W Deininger; Brian J Druker
Journal:  J Clin Invest       Date:  2010-12-13       Impact factor: 14.808

5.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Authors:  Neil P Shah; John M Nicoll; Bhushan Nagar; Mercedes E Gorre; Ronald L Paquette; John Kuriyan; Charles L Sawyers
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

6.  Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.

Authors:  Luana Casetti; Séverine Martin-Lannerée; Imen Najjar; Isabelle Plo; Sylvie Augé; Lydia Roy; Jean-Claude Chomel; Evelyne Lauret; Ali G Turhan; Isabelle Dusanter-Fourt
Journal:  Cancer Res       Date:  2013-02-11       Impact factor: 12.701

7.  BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

Authors:  Hilmar Quentmeier; Sonja Eberth; Julia Romani; Margarete Zaborski; Hans G Drexler
Journal:  J Hematol Oncol       Date:  2011-02-07       Impact factor: 17.388

8.  Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.

Authors:  Nadine N Bewry; Rajesh R Nair; Michael F Emmons; David Boulware; Javier Pinilla-Ibarz; Lori A Hazlehurst
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261
  8 in total
  9 in total

Review 1.  Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Authors:  Ami B Patel; Thomas O'Hare; Michael W Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2017-08       Impact factor: 3.722

Review 2.  Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors.

Authors:  Wei-Chih Chen; Gangqing Hu; Lori A Hazlehurst
Journal:  Curr Opin Pharmacol       Date:  2020-09-06       Impact factor: 5.547

Review 3.  Transcriptional Regulation of Emergency Granulopoiesis in Leukemia.

Authors:  Shirin Hasan; Afsar R Naqvi; Asim Rizvi
Journal:  Front Immunol       Date:  2018-03-12       Impact factor: 7.561

4.  Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.

Authors:  Karoline V Gleixner; Mathias Schneeweiss; Gregor Eisenwort; Daniela Berger; Harald Herrmann; Katharina Blatt; Georg Greiner; Konstantin Byrgazov; Gregor Hoermann; Marina Konopleva; Islam Waliul; Abbarna A Cumaraswamy; Patrick T Gunning; Hiroshi Maeda; Richard Moriggl; Michael Deininger; Thomas Lion; Michael Andreeff; Peter Valent
Journal:  Haematologica       Date:  2017-06-08       Impact factor: 9.941

5.  Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms.

Authors:  Ami B Patel; Anthony D Pomicter; Dongqing Yan; Anna M Eiring; Orlando Antelope; Jonathan A Schumacher; Todd W Kelley; Srinivas K Tantravahi; Tibor J Kovacsovics; Paul J Shami; Thomas O'Hare; Michael W Deininger
Journal:  Leukemia       Date:  2020-05-14       Impact factor: 11.528

6.  Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B.

Authors:  Alfonso E Bencomo-Alvarez; Andres J Rubio; Idaly M Olivas; Mayra A Gonzalez; Rebecca Ellwood; Carme Ripoll Fiol; Christopher A Eide; Joshua J Lara; Christian Barreto-Vargas; Luis F Jave-Suarez; Georgios Nteliopoulos; Alistair G Reid; Dragana Milojkovic; Brian J Druker; Jane Apperley; Jamshid S Khorashad; Anna M Eiring
Journal:  Oncogene       Date:  2021-03-12       Impact factor: 9.867

7.  The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission.

Authors:  Sandrine Jeanpierre; Kawtar Arizkane; Supat Thongjuea; Elodie Grockowiak; Kevin Geistlich; Lea Barral; Thibault Voeltzel; Anissa Guillemin; Sandrine Gonin-Giraud; Olivier Gandrillon; Franck-Emmanuel Nicolini; Adam J Mead; Véronique Maguer-Satta; Sylvain Lefort
Journal:  Haematologica       Date:  2021-01-01       Impact factor: 9.941

Review 8.  Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia.

Authors:  Govinda Poudel; Molly G Tolland; Timothy P Hughes; Ilaria S Pagani
Journal:  Cancers (Basel)       Date:  2022-07-06       Impact factor: 6.575

Review 9.  BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.

Authors:  Gustavo P Amarante-Mendes; Aamir Rana; Tarcila Santos Datoguia; Nelson Hamerschlak; Gabriela Brumatti
Journal:  Pharmaceutics       Date:  2022-01-17       Impact factor: 6.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.